Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen

Shionogi President Isao Teshirogi Shionogi saw its group sales rise 5.5% in the year ended in March thanks to growth in royalty income tied to its HIV franchise, Tivicay (dolutegravir) and Triumeq (dolutegravir + abacavir + lamivudine), according to its...read more